Parkinson's disease (PD) begins years before motor onset. Biomarkers are needed to detect early disease, stratify risk, and monitor progression. Through proximity extension assay profiling of the cerebrospinal fluid (CSF) proteome, we investigated early neuronal a-synuclein disease (NSD) in independent cohorts (discove...
S. Weber, Y. Zaplatnikov, Y. Kyriachenko et al.· medRxiv· 0 citations
Genome-wide association studies of alcohol use disorder (AUD) have identified >100 loci, yet the functional impact and the downstream molecular mechanisms are not well understood. As functional effectors of genes, proteins provide direct insight into disease mechanisms. However, most proteomic alterations in postmortem...
Xin-Di Li, Andrew J. Boreland, Arpana Agrawal et al.· bioRxiv· 0 citations
It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...
B. Bellaver, G. Povala, P. C. L. Ferreira et al.· Molecular Neurodegeneration· 0 citations
These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.
Saima Rathore, E. Dammer, Anantharaman Shantaraman et al.· Molecular Neurodegeneration· 0 citations
GCH1 pathogenic variants were associated with a clinically distinct phenotype characterized by earlier disease onset and slower progression of motor complications, suggesting that GCH1 genetic variants may serve as genetic biomarkers for patient stratification and prognosis in PD.
J. Shin, M. T. Periñán, J. W. Jang et al.· medRxiv· 0 citations
PGS demonstrated clinically meaningful risk prediction for substance use disorders in EA and LA, supporting the feasibility of future clinical implementation for population-level screening and underscoring the urgent need for more genetic studies in that population.
Dong-Bing Lai, Michael Zhang, Tae-Hwi Schwantes-An et al.· medRxiv· 0 citations
Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...
H. Oh, J. Downer, Connor D. Dietz et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
